Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function. Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease

American Heart Journal

Volumn 151, Issue 6, 2006, Pages 1240-1246

  van Gilst, Wiek H ^a   Warnica, J Wayne ^b   Baillot, Richard ^c   Johnstone, David ^d   Calciu, Cristina Dana ^e   Block, Pierre ^f   Myers, Martin G ^g   Chocron, Sidney ^h   Rouleau, Jean Lucien ⁱ  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF CALGARY   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e PFIZER INC   (United States)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITÉ DE FRANCHE COMTÉ   (France)

ⁱ MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; QUINAPRIL; RADIOISOTOPE; RAMIPRIL; TRANDOLAPRIL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; INTRACARDIAC THROMBOSIS; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MYOCARDITIS; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; STABLE ANGINA PECTORIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 33744991490     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.07.010     Document Type: Article

References (16)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
2. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
3. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327 (1992) 669-677
4. Yusuf S., Pepine C., Garces C., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340 (1992) 1173-1178
5. Rutherford J.D., Moye L.A., Pfeffer M.A., et al., for the SAVE investigators. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial (SAVE). Circulation 90 (1994) 1731-1738
6. Lonn E.M., Yusuf S., Jha P., et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90 (1994) 2056-2069
7. Pitt B., O'Neill B., Feldman R., et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 87 (2001) 1058-1063
8. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 12 (1996) 127-137
9. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
10. Pfeffer M.A., Domanski M., Rosenberg Y., et al. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Am J Cardiol 82 (1998) 25H-30H
11. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
12. Warnica J.W., van Gilst W.H., Baillot R., et al. Ischemia management with accupril post bypass graft via inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial-design and rationale. Can J Cardiol (2002) 1191-1200
13. Vantrimpont P., Goedhart D.M., Bertrand M.E., et al. Risk assessment and risk reduction by perindopril in patients with stable coronary artery disease. Circulation 110 (2004) III-545
14. Oosterga M., Voors A.A., Buikema H., et al. Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. Cardiovasc Drugs Ther 14 (2000) 55-60
15. Johnstone C.I., Fabris B., Yamada H., et al. Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors. J Hypertens 7 Suppl 5 (1989) S11-S16
16. Oosterga M., Voors A.A., Pinto Y.M., et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). Am J Cardiol 87 (2001) 542-546